News Sentiment

TPST sentiment intelligence

Tempest Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.97 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-10.7% over one week, -22.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -10.7% Price reacting lower
Trend fit Trend inactive -22.8% over four weeks
Fair value -94.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 43
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
GlobeNewswire 9
TradingView 7
Market source 6
TradingKey 3
MT Newswires 2
Investing.com Nigeria 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 17
Deals and strategy 5
Regulatory and legal 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-56 of 56